Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance
Elif Karaaslan, Amy Whitesell, Jason Malenfant, William C. Carson, Michael Townsend, Kasongo Kayembe Jolie, Enogo Koivogui, Siba Michel Grovogui, Boubacar Diallo, Nouonan Gbamou, Salomon Corvil, Sanaba Boumbaly, Lise Martel, Julie R. Sinclair, Alimou Camara, Trevor Shoemaker, Mary J. Choi, Joel M. Montgomery, Christina F. Spiropoulou, and Éric Bergeron
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E. Karaaslan, A. Whitesell, J. Malenfant, W.C. Carson, M. Townsend, L. Martel, J.R. Sinclair, T. Shoemaker, M.J. Choi, J.M. Montgomery, C.T. Spiropoulou, É. Bergeron); African Field Epidemiology Network, Conakry, Guinea (K.K. Jolie, S. Corvil); Ministry of Health, Conakry (E. Koivogui, S.M. Grovogui); US Centers for Disease Control and Prevention, Conakry (B. Diallo); Agence Nationale de Sécurité Sanitaire, Conakry (N. Gbamou); International Center for Research of Tropical Infections in Guinea, N’Zerekore, Guinea (S. Boumbaly); Ministry of Higher Education, Scientific Research, and Innovation, Conakry (A. Camara); University of Georgia, Athens, Georgia, USA (É. Bergeron).
Main Article
Figure 1
Figure 1. Antigen selection and assay optimization for study of development of multiplex assay to confirm Ebola vaccination. A) Schematic illustration of the rVSV∆G-ZEBOV-GP genome and proteins used in the assay design. Orange indicates the shared portion in GP1 and sGP. del21-nucleoprotein denotes the deletion of the N terminal 21 amino acids of VSV nucleoprotein. B–D) The effect of coupling protein concentration on detection was measured as MFI/50 beads by using mAb114 for EBOV GP1,2 (B) and EBOV sGP (C) and a serum sample from an ERVEBO vaccinee for VSV-P-N (D). Figure created using BioRender (https://www.biorender.com). Avi-tag, Avidin tag; Biot, protein biotinylation; EBOV, Ebola virus; GP, glycoprotein; His-tag, histidine tag; L, large RNA polymerase; M, matrix; mAB, monoclonal antibody; MFI, mean fluorescence intensity; N, nucleocapsid; P, phosphoprotein; P peptide, the first 60 amino acids of the VSV phosphoprotein; rVSV∆G-ZEBOV-GP, recombinant vesicular stomatitis virus where VSV glycoprotein G gene is deleted and replaced with the Ebola virus glycoprotein gene; sGP, secreted glycoprotein; VSV, vesicular stomatitis virus; VSV-P-N, vesicular stomatitis virus nucleoprotein N-terminally fused with P peptide.
Main Article
Page created: March 04, 2026
Page updated: March 30, 2026
Page reviewed: March 30, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.